• The hospital-related costs of thromboembolism associated to cancer were investigated in French patients with breast or prostate cancer diagnosed in 2010. Cost evaluation was done over a 2-year follow-up period.
• Among 107,916 new breast and prostate cancer cases, 2,268 patients were hospitalized for thromboembolism. 15% of those patients experienced recurrent events, representing 19% of total admissions.
• Mean cost of hospital stay for thromboembolism ranged from € 2,916 to € 3,611, depending on cancer type and thromboembolic event type (first or recurrent).
• For one patient with recurrence, overall mean cost ranged from € 5,545 to € 5,692 over the 2-year follow-up.
• Overall hospital expenditure for thromboembolism in breast and prostate cancer patients reached € 3.4 millions (€ 334,579 for recurrent events) over two years.